Introduction/Overview
Steroid sapogenins are a class of secondary metabolites widely present in nature, with a four ring steroid nucleus structure, and are the glycosides of various medicinal saponins. These compounds play an important role in both traditional medicine and modern drug development due to their diverse biological activities. Tigogen, also known as (25R) -5 α - spirostane-3 β - ol, is a typical spirostane type steroidal sapogenin. Since its discovery, it has been an important intermediate in the fields of organic synthesis and steroid drug chemistry due to its unique chemical structure. However, research in the past two decades has gradually revealed that sisal sapogenin itself has rich and significant pharmacological activities, far beyond being used as a precursor for synthesis.
Modern pharmacological research has shown that sisal sapogenins have great potential in anti-tumor, anti-inflammatory, regulating bone metabolism, protecting the cardiovascular system, and regulating immunity. It can inhibit the proliferation of a variety of tumor cells and induce apoptosis, regulate the activities of osteoblasts and osteoclasts to fight osteoporosis, inhibit the release of inflammatory factors, and show a protective effect in metabolic cardiovascular disease models such as atherosclerosis. These activities make it a potential candidate molecule for the treatment of breast cancer, rheumatoid arthritis, osteoporosis, atherosclerosis and other major diseases. This article aims to systematically review the chemical properties, plant sources, pharmacological activities, molecular mechanisms of action, pharmacological evaluation, and clinical application prospects of sisal sapogenin, in order to provide comprehensive scientific references for the in-depth research and development of this natural product.
Chemical structure and physicochemical properties
The molecular formula of sisal sapogenin (CAS number: 77-60-1) is C27H44O3, with a molecular weight of 416.6460. Its core structure is 5 α - spirostane, which belongs to spirostane alcohol compounds. Specifically, its steroid core A/B ring is trans fused (5 α - H), and the C/D ring is also trans fused. There is a β - configuration hydroxyl group at the C-3 position, which is its main polar group. Its structural feature is that the C-22 position is a spiro atom, connected to an oxygen-containing F ring (pentagonal furan ring), forming a characteristic spirostane structure, with an absolute configuration of 25R type.
Based on its chemical structure, sisal sapogenins exhibit typical physicochemical properties of steroidal sapogenins. The calculated lipid water partition coefficient (LogP) is 5.44, indicating that the compound has a high degree of lipophilicity. The topological polar surface area (TPSA) is relatively low, at 38.69 Å ². These parameters determine its extremely low water solubility (about 0.0002 mg/mL), and it has good solubility in organic solvents such as methanol, ethanol, chloroform, and ethyl acetate. High lipophilicity and low TPSA also indicate its high blood-brain barrier permeability potential, which provides the possibility for its application in the study of central nervous system related diseases. The preliminary drug risk assessment shows that the Ames test result is negative (0.0), indicating no mutagenicity; At the same time, it has no significant inhibitory effect on hERG potassium channels, reducing the potential risk of heart QT interval prolongation and providing preliminary positive data for its safety evaluation.
Plant sources and extraction methods
The main sources of sisal saponins are Agavaceae and Liliaceae plants. Its name "Jianma" directly refers to its main natural source - Jianma (Agave sisalana), which is an important fiber crop. Its leaves contain abundant steroidal saponins, which can be hydrolyzed to obtain a mixture of saponins mainly composed of Jianma sapogenins, Haike sapogenins, etc. In addition, it is widely present in plants of the same genus, such as Agave Americana, Polianthes tuberosa, and Veratrum.
The extraction and separation of sisal saponins from plant materials usually follow the following process: first, dry plant tissues (such as sisal leaves or rhizomes) are crushed, heated with alcohol solvents (such as methanol or ethanol) under reflux or ultrasound assisted extraction, to obtain crude total saponin extract. Subsequently, the crude extract is subjected to acid hydrolysis (usually using hydrochloric acid or sulfuric acid) to hydrolyze the bound saponins, releasing lipophilic sapogenins. After neutralization and filtration, the hydrolyzed mixture is extracted with low polarity organic solvents such as petroleum ether and ethyl acetate to obtain crude sapogenin. Further purification is often carried out using silica gel column chromatography, with different ratios of petroleum ether ethyl acetate or chloroform methanol gradient elution, combined with thin layer chromatography (TLC) or high performance liquid chromatography (HPLC) monitoring, to separate high-purity sisal saponin monomers. Modern technologies such as high-speed countercurrent chromatography (HSCCC) have also been applied for their efficient preparation and separation. With the development of synthetic biology, the biosynthesis of steroidal sapogenins using microbial cell factories has become a research hotspot, providing a new approach for the large-scale and sustainable acquisition of sisal sapogenins.
Pharmacological activity research
A large number of in vitro and in vivo studies have confirmed that sisal saponins have various pharmacological activities, covering fields such as anti-tumor, anti-inflammatory, regulation of bone metabolism, cardiovascular protection, and immune regulation.
1. Antitumor activity
Jianma saponins exhibit broad-spectrum growth inhibition and pro apoptotic effects on various human cancer cell lines. Studies have shown that it can effectively inhibit the proliferation of breast cancer (such as MCF-7, MDA-MB-231 cells), liver cancer, colon cancer, lung cancer and ovarian cancer, and its effect is concentration and time dependent. In the breast cancer model, sisal saponin can not only induce apoptosis of cancer cells, but also inhibit their migration and invasion, suggesting that it has anti metastasis potential. Animal experiments have also confirmed its anti-tumor effect in vivo. In the transplanted tumor mouse model, the administration of sisal saponins can significantly inhibit tumor growth without significant toxicity.
2. Anti inflammatory and immune regulatory activity
Jianma saponins have shown strong anti-inflammatory effects in both acute and chronic inflammation models. It can significantly inhibit the production of nitric oxide (NO), prostaglandin E2 (PGE2), and pro-inflammatory cytokines (such as TNF - α, IL-1 β, IL-6) in macrophages induced by lipopolysaccharide (LPS). In animal models of rheumatoid arthritis, such as collagen induced arthritis rats, treatment with sisal saponins can alleviate joint swelling, cartilage destruction, and inflammatory cell infiltration. Its effect is closely related to regulating immune cell function and inhibiting inflammatory signaling pathways.
3. Regulatory effect on bone metabolism (anti osteoporosis)
Jianma saponin plays the role of a "bidirectional regulator" in bone metabolism regulation. On the one hand, it can inhibit the differentiation of mouse bone marrow stromal cells into adipocytes; On the other hand, it can promote its differentiation into osteoblasts, enhance alkaline phosphatase (ALP) activity, and promote the formation of mineralized nodules, indicating its bone promoting effect. Meanwhile, research has also found that sisal saponins can inhibit the differentiation and bone resorption activity of osteoclasts. This characteristic of promoting bone formation and inhibiting bone resorption gives it unique advantages in preventing and treating osteoporosis, which has been validated in a rat model of osteoporosis induced by ovariectomy.
4. Cardiovascular protective activity
In the study of atherosclerosis, sisal saponins showed protective potential. Its mechanism may be involved in regulating lipid metabolism, such as reducing oxidized low-density lipoprotein (ox LDL) induced macrophage foam, and inhibiting the abnormal proliferation and migration of vascular smooth muscle cells. In addition, its anti-inflammatory and antioxidant properties also help to reduce vascular endothelial damage and the formation and development of atherosclerotic plaque.
Mechanism of action and molecular targets
The various pharmacological activities of sisal saponins stem from their multidimensional regulation of multiple signaling pathways and key targets within cells.
1. Mechanism of anti-tumor action
The core of its anti-tumor effect is to induce cell apoptosis and cycle arrest, involving multiple molecular targets:
* Regulating apoptosis related proteins Jianma saponin can downregulate the expression of anti apoptotic proteins B cell lymphoma 2 (BCL2) and myeloid leukemia 1 (MCL1), while possibly upregulating pro apoptotic proteins, disrupting mitochondrial membrane potential, leading to the release of cytochrome C, thereby activating the caspase cascade reaction and triggering endogenous apoptosis.
* Inhibition of STAT3 signaling pathway Signal transduction and transcription activator 3 (STAT3) is an important oncogenic transcription factor. Jianma saponin can inhibit the phosphorylation (activation) of STAT3, suppress its nuclear translocation, and downregulate the expression of downstream target genes (such as Cyclin D1, Bcl-2, MMP2), thereby inhibiting cell proliferation, survival, and invasion.
* Affects estrogen signaling: For estrogen receptor positive (ER+) breast cancer, sisal saponin is found to be an antagonist of estrogen receptor alpha (ESR1) and can inhibit the activity of aromatase (CYP19A1), thereby reducing the synthesis of endogenous estrogen and cutting off the growth signal of estrogen dependent tumors.
* Inhibition of Topoisomerase and HIF-1 αResearch suggests that sisal saponins may inhibit the activity of topoisomerases I (TOP1) and II α (TOP2A), interfering with DNA replication and repair. At the same time, it can downregulate the expression of hypoxia inducible factor-1 α (HIF1A), inhibit tumor adaptation to hypoxic microenvironment and angiogenesis.
* Regulating the MAPK pathway As a key pathway for cell proliferation and stress response, the activity of mitogen activated protein kinase (MAPK) family members such as MAPK1 (ERK2) may also be regulated by sisal sapogenin, but its specific action (inhibition or activation) may be cell type dependent.
2. Anti inflammatory and bone regulating mechanisms
Its anti-inflammatory effect is closely related to the inhibition of the activation of nuclear factor kappa B (NF - κ B) and MAPK inflammatory signaling pathways, reducing the transcription of downstream inflammatory mediators. In terms of promoting bone formation, its mechanism may involve activating classic osteogenic differentiation pathways such as BMP-2/Smad or Wnt/β - catenin. The inhibition of osteoclasts is related to interference with RANKL/RANK/OPG system signaling and inhibition of key osteoclast transcription factors such as NFATc1.
Evaluation of drug properties and pharmacokinetics
Although the pharmacological activity of sisal saponins is significant, their medicinal properties still face challenges, and related pharmacokinetic studies are still in their early stages.
Pharmacokinetic properties Due to its extremely low water solubility, the oral bioavailability of sisal sapogenin may be limited. Limited animal pharmacokinetic studies have shown that its oral absorption is slow, it is widely distributed in the body, and its high lipid solubility and blood-brain barrier permeability suggest that it may be distributed in adipose tissue and able to enter the central nervous system. In terms of metabolism, as a steroid compound, it is likely to undergo phase I (such as CYP450 enzyme catalyzed hydroxylation) and phase II (such as glucuronidation and sulfation) metabolism in the liver. The prototype drug and its metabolites may mainly be excreted through bile and feces. Currently, there is a lack of systematic human pharmacokinetic data.
Challenges and optimization strategies for drug development：
1. Solubility and bioavailability Low water solubility is its main bottleneck. The key direction to enhance its drug properties is to use pharmaceutical methods for modification, including preparing nanocrystals, liposomes, micelles, solid dispersions, or cyclodextrin inclusion complexes to significantly improve its solubility and dissolution rate.
2. Structural modification Using it as the parent nucleus for chemical structural modification, introducing hydrophilic groups or designing prodrugs, is the fundamental strategy to improve its physicochemical properties and pharmacokinetic behavior. For example, in the C-3 hydroxyl group or through F-ring modification to synthesize derivatives, previous studies have shown that some derivatives have improved water solubility and selectivity while maintaining or enhancing activity.
3. safety Although the preliminary screening for genetic toxicity (Ames) and cardiac toxicity (hERG) was negative, a comprehensive preclinical safety evaluation is still needed, including long-term toxicity, reproductive toxicity, etc., to clarify its safety window.
Clinical application prospects and prospects
As a multi-target and multifunctional natural product lead compound, sisal sapogenin has shown broad application prospects in the treatment of various chronic and complex diseases.
Potential clinical application directions：
* Tumor adjuvant therapy and chemoprevention It is especially suitable for patients with breast cancer (especially ER+), bone related tumors and those who are resistant to traditional chemotherapy. Its multi-target characteristics help overcome the resistance problem of single target drugs.
* Treatment of osteoporosis Its unique dual effects of promoting bone formation and inhibiting bone resorption make it a promising new type of anti osteoporosis drug, which is superior to current mainstream drugs that only promote bone resorption or resorption.
* Inflammatory and autoimmune diseases Such as rheumatoid arthritis, inflammatory bowel disease, etc., their anti-inflammatory and immune regulatory effects have therapeutic value.
* cardiovascular disease To explore as a potential drug for the prevention and treatment of atherosclerosis.
Future research prospects：
1. In depth mechanism exploration It is necessary to use chemical biology methods (such as affinity fishing, proteomics) to discover its direct target and elucidate its initial molecular event of action.
2. Systematic pharmacokinetics and toxicology research Systematic preclinical pharmacokinetic and toxicological studies that comply with regulations must be conducted to clarify their in vivo processes and safety limits.
3. Structural optimization and formulation development We should strengthen the rational drug design based on structure, and synthesize derivatives with higher activity, better selectivity, and better pharmacokinetic properties; At the same time, we will vigorously promote the research and development of new drug delivery systems.
4. Combination therapy research Exploring the combined use of sisal saponins and existing clinical drugs (such as chemotherapy drugs and anti osteoporosis drugs) may produce synergistic effects, reducing their respective dosages and toxic side effects.
5. clinical translation Based on sufficient preclinical research, promote high-quality pharmacological and safety evaluations to lay the foundation for its ultimate clinical trials.
Conclusion
Jianma sapogenin, a steroidal sapogenin found in plants such as Jianma, has transformed from a traditional chemical intermediate into a star natural product with rich pharmacological activity and diverse mechanisms of action. Its outstanding performance in anti-tumor, anti-inflammatory, bone metabolism regulation and cardiovascular protection reveals its great potential as a lead compound of innovative drugs for the treatment of breast cancer, osteoporosis, arthritis and other major diseases. Despite facing challenges in drug formulation such as solubility and bioavailability, these obstacles are expected to be overcome through modern drug chemical structure modification and the empowerment of new formulation technologies. In the future, with a more refined analysis of its molecular mechanism of action and the advancement of systematic preclinical research, sisal sapogenin and its optimized derivatives are expected to make breakthroughs in the field of innovative drug development, contributing the power of natural products to human health.
